TENAX THERAPEUTICS, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Tenax Therapeutics is a biopharmaceutical company developing therapies for cardiopulmonary diseases, including treatments for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Doogan DeclanInsider | Buy | $102K | 53,000at $1.92 | Sep 16, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $1.27M | 716,369at $1.77 | Aug 21, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $360K | 202,124at $1.78 | Aug 20, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $188K | 107,374at $1.75 | Aug 24, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable TENX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.